ATE289800T1 - Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems - Google Patents
Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystemsInfo
- Publication number
- ATE289800T1 ATE289800T1 AT99966114T AT99966114T ATE289800T1 AT E289800 T1 ATE289800 T1 AT E289800T1 AT 99966114 T AT99966114 T AT 99966114T AT 99966114 T AT99966114 T AT 99966114T AT E289800 T1 ATE289800 T1 AT E289800T1
- Authority
- AT
- Austria
- Prior art keywords
- nervous system
- central nervous
- treatment
- medication
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20853998A | 1998-12-09 | 1998-12-09 | |
PCT/US1999/029335 WO2000033814A2 (en) | 1998-12-09 | 1999-12-09 | Method for administering agents to the central nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE289800T1 true ATE289800T1 (de) | 2005-03-15 |
Family
ID=22774961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99966114T ATE289800T1 (de) | 1998-12-09 | 1999-12-09 | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1135105B1 (de) |
JP (1) | JP2002531490A (de) |
AT (1) | ATE289800T1 (de) |
AU (1) | AU2173400A (de) |
DE (1) | DE69923998T2 (de) |
WO (1) | WO2000033814A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1305294B1 (it) | 1999-01-29 | 2001-05-04 | Alessandro Lambiase | Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari. |
EP1602378A1 (de) * | 1999-12-09 | 2005-12-07 | Chiron Corporation | Verfahren zur Verabreichung von Wirkstoffen in das zentrale Nervensystem oder Lymphsystem |
AU783208B2 (en) * | 1999-12-09 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | Method for administering a cytokine to the central nervous system and the lymphatic system |
CA2597525A1 (en) * | 2005-02-17 | 2006-08-24 | Senju Pharmaceutical Co., Ltd. | Solid ophthalmic drug for external use |
US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
ITRM20050447A1 (it) * | 2005-08-19 | 2007-02-20 | Anabasis S R L | Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. |
WO2007025249A2 (en) | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
US8153604B2 (en) | 2006-04-24 | 2012-04-10 | Geron Corporation | CNS-tumor treatment method and composition |
EP2173344B1 (de) * | 2007-06-29 | 2016-04-06 | Clarencew Pty Ltd. | Behandlung oder prophylaxe von neurologischen oder neuropsychiatrischen erkrankungen durch okulare verabreichung |
US8778904B2 (en) | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
US8987199B2 (en) | 2011-06-15 | 2015-03-24 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
SG11201509419QA (en) | 2013-05-15 | 2015-12-30 | Univ Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
CN107249567B (zh) | 2014-11-21 | 2021-08-03 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
EP3224341B1 (de) | 2014-11-25 | 2021-05-19 | Corning Incorporated | Zellkulturmedium erweiternde materialien und verfahren |
PT3242676T (pt) | 2015-01-07 | 2023-12-06 | TONIX Pharmaceuticals Holding Corp | Formulações de ocitocina que contém magnésio e métodos de uso |
WO2017017543A1 (en) * | 2015-07-30 | 2017-02-02 | U R Anoop | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
US11207461B2 (en) * | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
SG10201912761UA (en) | 2016-04-15 | 2020-02-27 | The Trustees Of The Univ Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
WO2018048789A1 (en) * | 2016-09-07 | 2018-03-15 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
EP3684938A1 (de) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gentherapie zur behandlung von mukopolysaccharidose typ ii |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3585618D1 (de) * | 1984-10-19 | 1992-04-16 | Chiron Corp | Anregung zur heilung einer wunde mittels menschlichen hautwachstumsfaktors hergestellt durch rekombinant-dns. |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
CA2167104A1 (en) * | 1995-01-17 | 1996-07-18 | Joerg G.D. Birkmayer | Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
JP3191038B2 (ja) * | 1996-06-26 | 2001-07-23 | 輝夫 西田 | 眼科用医薬組成物 |
US5840736A (en) * | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
IT1289608B1 (it) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale |
-
1999
- 1999-12-09 AU AU21734/00A patent/AU2173400A/en not_active Abandoned
- 1999-12-09 JP JP2000586308A patent/JP2002531490A/ja active Pending
- 1999-12-09 AT AT99966114T patent/ATE289800T1/de not_active IP Right Cessation
- 1999-12-09 EP EP99966114A patent/EP1135105B1/de not_active Expired - Lifetime
- 1999-12-09 WO PCT/US1999/029335 patent/WO2000033814A2/en active IP Right Grant
- 1999-12-09 DE DE69923998T patent/DE69923998T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2002531490A (ja) | 2002-09-24 |
AU2173400A (en) | 2000-06-26 |
EP1135105A2 (de) | 2001-09-26 |
DE69923998D1 (de) | 2005-04-07 |
WO2000033814A3 (en) | 2000-11-30 |
EP1135105B1 (de) | 2005-03-02 |
WO2000033814A2 (en) | 2000-06-15 |
DE69923998T2 (de) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE289800T1 (de) | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems | |
DE68908971T2 (de) | Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen. | |
DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
IL157413A0 (en) | Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands | |
DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
DE69616376T2 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
DE60042137D1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
DE60125335D1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
DE69903750T2 (de) | Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten | |
ATE326956T1 (de) | Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität | |
UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
ATE250420T1 (de) | Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten | |
DE69331605T2 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
WO2002066469A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands | |
ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
AP9901473A0 (en) | Use of benzopyranols to treat neurological disorders. | |
DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
WO2002066468A3 (en) | Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands | |
DE68928169D1 (de) | Zusammensetzung zur Behandlung von degenerativen Krankheiten des Nervensystems | |
DE69630055D1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation | |
DE69424415T2 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |